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Abstract  
Objective: Human Papillomavirus (HPV) infection is clearly associated with cervical cancer development. 
However, only a very small percentage of HPV-infected women will eventually develop cancer and the factors 
determining that progression have not yet been sufficiently clarified. It is known that HPV oncoproteins E6 and E7 
interact with various squamous cell molecules towards promoting cell immortalization and carcinogenesis. Among 
these molecules are the proapoptotic proteins Bax and Bak, two key regulators of the intrinsic apoptotic pathway. 
The aim of this study is to test for possible statistically significant differences in the Bax and Bak expression in the 
Pap smears of HPV-positive and HPV-negative women and thus examine their potential value as prognostic 
markers.  
Methods: One hundred and twenty women were subtyped for HPV using microarrays hybridization and then Bax 
and Bak expression was assessed using immunocytochemistry staining on cytocentrifuged ThinPrep samples.  
Results: Statistical analysis determined that there was no statistically significant difference between the expression 
of Bax and Bak in the HPV-positive and HPV-negative women as this expression was detected by 
immunocytochemical assessment of ThinPrep samples.  
Conclusion: Although in several published studies there is evidence of HPV oncoproteins affecting the expression 
of Bax and Bak on squamous cells, our study indicates that this effect is not apparent by immunocytochemical 
protein staining. 
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Introduction 
Cancer of the uterine cervix is the second 
most frequent women’s cancer worldwide, 
with an incidence of 18,7/100000 women [1], 
as well as the second leading cause of cancer 
related deaths among women [2]. It accounts 
for 5% of the global tumor burden [2] and its 
mortality rate between 1980 and 2005 was 
between 1.44 and 2.48 deaths per 100000 
women [1]. In Greece in particular, the overall 
incidence is estimated to be approximately 
10.4-10.6/100000, although a slight increase 
is anticipated to occur in the following years 
due to the increased influx of immigrants 
from developing countries [3].
 
 
Human Papillomavirus (HPV) is to date the 
only microorganism whose presence and the 
lesions it causes in squamous cervical cells 
have been clearly correlated with 
precancerous cervical lesions. HPV DNA has 
been detected in 99.7% of squamous cervical 
cells and 94-100% of adenocarcinomas and 
adenosquamous carcinomas [4]. The HPV 
types that are most commonly detected in 
them are 16, 18, 45, 31, 33, 52, 58 and 35 
[5-7]. HPV 16 and HPV 18 are responsible for 
approximately 70% of cervical cancers [2]. 
For HPV 16 and HPV 18 in particular there is 
also strong evidence of its being a causative 
agent in cancer of the vulva, vagina, penis, 
anus, oral cavity and oropharynx [8]. 
However, HPV infection is a necessary but 
not adequate condition for cervical cancer 
development. Eighty per cent of HPV 
infections are transient [4], whereas only 5% 
of them progress to cervical intraepithelial 
neoplasia, and only 10-20% of cervical 
intraepithelial neoplasias progress to cancer 
[9]. Therefore, the clarification of the 
mechanism by which HPV leads to 
carcinogenesis is of great clinical significance, 
as it would go a long way towards elucidating 
which other factors collaborate with HPV 
infection in order for normal squamous 
epithelium to undergo carcinogenesis, and 
possibly lead to discovering more efficient 
methods of treatment and prevention.  
High-risk HPV types like HPV 16 and HPV 
18 encode oncoproteins E6 and E7 which are 
considered the primary factors responsible for 
blocking cell cycle exit during cell 
differentiation, eventually leading to 
immortalization of the cell [10]. E6 induces 
ubiquitination and subsequent degradation of 
the tumor suppressor gene p53 whereas E7 
inactivates the tumor suppressor gene pRb 
causing increased DNA synthesis and cell 
division [11]. There is also evidence 
indicating that E6 and E7 decrease the 
expression of proapoptotic proteins Bax and 
Bak whilst increasing the expression of 
antiapoptotic protein Bcl-2, apparently 
independently of p53 ubiquitination [11-14].  
Bax and Bak are key regulators of the 
intrinsic (mitochondrial) apoptotic pathway 
and their expression is of great significance in 
physiological and pathological processes such 
as homeostasis and cancer [15]. They are 
members of the pro-apoptotic subgroup of the 
Bcl-2 family of proteins, which constitutes a 
pivotal checkpoint in the apoptotic process 
[16]. More specifically, when cells are 
deprived of survival signals anti-apoptotic 
proteins such as Bcl-2 and Bcl-xL are lost 
from the mitochondrial membrane and 
replaced by pro-apoptotic proteins such as 
Bax, Bak and Bim [17].
 
 These proteins 
increase the permeability of the outer 
mitochondrial membrane by forming pores 
[18], which are called mitochondrial-induced 
apoptosis channels (MAC). Through those 
pores proteins such as cytochrome c leak into 
the cytoplasm and activate the caspase 
cascade. It has been proven that Bax is a 
structural component of MAC while Bak too 
has been shown to co-immunoprecipitate with 
Bax during early apoptosis, and there is also 
data suggesting that it can replace Bax as a 
MAC component in Bax-deficient cells. 
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Therefore for a cell to become 
apoptosis-resistant both Bax and Bak need to 
be inactivated [15]. This makes them ideal 
targets for many viral oncoproteins, such as 
BHRF1 protein of the Epstein-Barr virus, the 
SV40 TAg protein and the adenovirus 
E1B19K protein [19]. However, the extent of 
the influence of Bax and Bak expression in 
squamous cervical cells carcinogenesis hasn’t 
been clearly determined yet, although certain 
studies indicate that the Bax-dependent 
proapoptotic pathway is a significant target of 
the E6 oncoprotein [20,21]. Other studies 
have demonstrated that the HPV16 and HPV 
18 E6 is capable of binding Bak and inhibiting 
Bak-induced apoptosis [13,19].
 
The purpose 
of this study is to examine whether there is 
statistically significant difference in the 
immunocytochemical expression of Bax and 
Bak in Pap smears of women positive for 
HPV infection, as opposed to women negative 
for HPV infection (control group), and, by 
extension, evaluate the possible usefulness of 
Bax and Bak immunocytochemical staining 
on cell samples as potential prognostic 
markers which could be implemented in the 
screening routine for cervical cancer in the 
future. A secondary smaller statistical analysis 
was conducted regarding the expression of 
Bax and Bak in Pap smears of women infected 
by HPV types 16 and 18 in particular, since 
they are the types whose effect on the 
functionality of Bax and Bak has been studied 
most extensively. The hypothesis of the study 
was “there is statistically significant 
difference between the staining of the Bax and 
Bak proteins in squamous epithelial cells of 
women infected with the HPV virus compared 
to women who are not infected, as it is 
expressed by the combination of the 
percentage of stained cells and the intensity of 
the staining.” 
Materials and Methods 
The women for this study were randomly 
selected; some of them had reported history of 
HPV infection but no HPV subtyping had 
been performed, whereas others had no prior 
history of HPV infection. After obtaining their 
informed consent, the women participating in 
this study had a conventional Pap smear and a 
Thin-Prep (PreservCyt Solution 20ml, Cytyc, 
Marlborough, Massachusetts, USA) sample 
for HPV subtyping taken with a flexible brush. 
Microarrays hybridization was used for HPV 
types subtyping. After HPV subtyping, 2ml of 
the ThinPrep solution were taken from each 
case. Each sample was centrifuged in a 
cytocentrifuge (Shandon Cytospin) at 
1200rpm for 5 minutes. The resulting slides 
were air-dried in room temperature for 30 
minutes and then stored in deep freeze (-8˚ to 
-15˚C).  
The immunocytochemical staining of the 
slides was carried out according to the 
ENVISION protocol 3-1 UNMASKING with 
MW for cellular smears (Dako, Glostrup, 
Denmark). For the detection of Bax and Bak 
proteins we used anti-human polyclonic rabbit 
antibodies (Rb Anti-Bax Pab, 7ml, 
ready-to-use, diluted 1:1 and  Rb Anti-Bak 
Pab, 7ml, ready-to-use, Spring Bioscience, 
USA), detection system EnVision/HRP 
Rabbit/Mouse, 100ml, ready-to-use (Dako, 
Glostrup, Denmark) with peroxidase and 
secondary antibodies against rabbit and mouse 
immunoglobulins molecules, and chromogen 
Liquid DAB + Chromogen, 50x Concentrate 
with Substrate Chromogen System, diluted 
1:50 (Dako, Glostrup, Denmark). Mayer 
hematoxylin was used for counterstain. 
The evaluation of the expression of the Bax 
and Bak protein was carried out by viewing at 
least 1000 cells per slide (50 40x power 
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fields) in order to be considered accurate. 
According to criteria cited in previous papers 
[22,23], evaluation of expression depends on 
two parameters: stain intensity and percentage 
of positive staining cells. Percentage of cells 
is graded as follows: 0: no reactive cells, 1: 
1-25%, 2: 26-50%, 3: 51-75%, 4: 76-100%. 
Stain intensity is graded as follows: 0: no 
staining, 1: weak staining, 2: moderate 
staining and 3: intense staining (see Figure 1 
for Bax and Figure 2, Figure 3 for Bak). The 
two values are multiplied and the result is the 
score for each field. If the field manifests 
heterogeneity, each separate area of the field 
is independently graded and the results are 
added together, e.g. if in a field 15% of the 
cells is intensely stained (1x3=3), 30% is 
moderately stained (2x2=4) and 55% is 
weakly stained (3x1=3), the field score is 
3+4+3=10. This method was preferred 
because it was considered by the authors as 
more precise and more liable to yield 
statistically significant results than the 
semiquantitative evaluation of stain intensity 
proposed by other authors [24,25]. It should 
be noted that all previously mentioned studies 
were conducted on paraffin-embedded tissue 
samples whereas in our study we used 
cytocentrifuged ThinPrep samples of cervical 
smears. To our knowledge, this is the first 
time this method is used on cell smears 
instead of tissue samples. 
Statistical analysis of the results was 
performed by use of the SPSS Statistic Packs 
17.0 program (SPSS Inc., Chicago, Illinois, 
USA). Statistically significant difference was 
calculated by means of the t-test, whereas the 
normality of score distribution was 
determined by skewness and kyrtosis and the 
Q-Q plots in groups with more than 50 cases, 
and with the Kolmogoroff-Smirnoff test in 
groups with less than 50 cases. In all cases, 
score distribution was normal. In all tests, p < 
0,05 was taken as the significance limit. 
 
 
Figure 1 Examples of negative, weak, moderate 
and strong Bax antibody staining intensity (Bax 
stain, x200). Negative staining, score 0 (thin 
arrow). Weak staining, score 1 (dashed arrow): 
hypochromatic, finely granular staining. Moderate 
staining, score 2 (wide arrow): denser, more 
hyperchromatic staining. Strong staining, score 3 
(arrowhead): Intensely hyperchromatic staining 
occupying the entire cell. The cell nucleus is 
barely visible. 
 
 
Figure 2 Examples of negative and strong Bak 
antibody staining intensity (Bak stain, x400). 
Negative staining, score 0 (thin arrow). Strong 
staining, score 3 (arrowhead). The staining 
features are the same as those of the Bax stain. 
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Figure 3 Examples of weak and moderate Bak 
antibody staining intensity (Bak stain, x200). 
Weak staining, score 1 (dashed arrow). Moderate 
staining, score 2 (wide arrow). The staining 
features are the same as those of the Bax stain. 
Results 
HPV Subtyping 
Samples of 120 patients were evaluated. Mean 
age was 33.4 (range, 16-62) years. Of the 120 
cases, 70 were negative for the examined HPV 
types and 50 were infected by 1 or more of the 
examined types. These numbers did not 
reduce the validity of statistical analysis in 
any way. More particularly, 33 cases were 
infected by 1 type, 11 by 2 types, 2 by 3 types, 
3 by 4 types and 1 by 5 HPV types. Of the 
detected types, the one more frequently 
encountered was type 42 in 12 cases, followed 
by types 44/55, 51, 59, 16, 31, etc. The 
frequency of the various types is displayed on 
Figure 4.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Frequency of the detected HPV types in the examined cases.  
 
Bax and Bak score statistical analysis 
The histograms of the Bax and Bak scores in all 120 
cases, and the histograms of the Bax and Bak scores 
in women positive for HPV and women negative for 
HPV (control group) as well as the average, 
minimum and maximum scores are listed in Figure 5 
and Figure 6. The question statistically analyzed was 
whether there was statistically significant difference 
between the Bax and Bak scores of a. women 
negative for HPV types (control group, n=70) and b. 
women positive for HPV types (n=50). The overall 
average Bax and Bak scores were 6.60 and 2.62 
respectively. The average Bax and Bak scores in the 
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control group were 6.56 and 2.68 respectively, 
whereas the average Bax and Bak scores in the 
HPV-positive group were 6.65 and 2.55 respectively. 
Statistical analysis by t-test showed that there is no 
statistically significant difference in the Bax and Bak 
scores between any of the aforementioned compared 
groups (p=0.810 for Bax and p=0.648 for Bak).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Panel A. Bax staining score histogram for all 
cases Panel B. Bax staining score histogram for 
HPV-positive cases Panel C. Bax staining score 
histogram for HPV-negative cases (control group). The 
mean, minimum and maximum score and standard 
deviation are displayed. In all histograms the 
distribution curve is normal. 
 
In our secondary analysis, the question 
statistically analyzed was whether there was 
statistically significant difference between the Bax 
and Bak scores of a. women positive for HPV types 
16 and 18 and b. women positive for HPV types 
other than 16 and 18. For validity purposes the 
scores of the subgroup positive for HPV 16 and HPV 
18 were also compared to the scores of the control 
group. Statistical analysis by t-test showed 
there is no statistically significant difference in the 
expression of Bax and Bak between the ‘HPV 
16/HPV 18 positive’ subgroup and the ‘other HPV 
types’ subgroup or between the ‘HPV 16/HPV 18 
positive’ subgroup and the control group (p=0.815 
for Bax and p=0.937 for Bak in the comparison 
between the two subgroups and p=0.739 for Bax and 
p=0.866 for Bak in the comparison between the 
‘HPV 16/HPV 18 positive’ subgroup and the control 
group).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Panel A. Bak staining score histogram for all 
cases Panel B. Bak staining score histogram for 
HPV-positive cases Panel C. Bak staining score 
histogram for HPV-negative cases (control group). The 
mean, minimum and maximum score and standard 
deviation are displayed. In all histograms the 
  
 
Ivy Union Publishing | http: //www.ivyunion.org February 15, 2014 | Volume 1 | Issue 1  
Klapsinou E et al. American Journal of Human Pathology 2014, 1:1-11 
6 
Page 7 of 11 
distribution curve is normal. 
Because the study did not yield statistically 
significant results, a post hoc power calculation of 
all t-tests performed in this study was conducted, 
in order to determine the study’s statistical power. 
According to the calculation the power of this 
study was below 10% in the performed t-tests. The 
significance of this finding will be further 
analyzed in the Discussion section. 
It should also be mentioned that in the two 
aforementioned studies where Bax and Bak were 
evaluated by both intensity and percentage of 
stained cells, the authors graded tumor cells only, 
taken from tissue sections of malignant neoplasms 
[22,23].
 
In our case, as this method was used as 
part of a routine screening test, most of the cells in 
the cell samples were normal, even in the 
HPV-positive women, since HPV infection does 
not always lead to visible cell alterations. Even in 
those cases where there were abnormal cells, their 
morphological assessment on the antibody-stained 
slides was problematic because most of the time 
the antibody staining obscured the cells’ 
morphological details. Therefore, the results 
obtained refer to a representative sample of 1000 
cells per slide, regardless of their morphological 
features, which we considered is in keeping with 
our approach of testing this method’s value as a 
screening test, adjunctive to the Papanicolaou test.  
Discussion 
Over the years quite a few studies have been 
conducted regarding the influence of HPV 
oncoproteins E6 and E7 in squamous cell 
carcinogenesis. Apart from their well-known 
ability to bind and inactivate the tumor suppressor 
genes p53 and pRb, there is evidence of them 
binding to a number of other proteins as well, 
including the proapoptotic proteins Bax and Bak, 
and several papers have been published regarding 
their effect on these proteins. The presence of such 
evidence naturally led to an investigation of a 
possible association between HPV oncoproteins 
and Bax and Bak expression in human squamous 
cells, both normal and cancerous. 
As mentioned above, strong causal association 
between HPV infection, especially by the HPV 16 
type [26], and head and neck squamous carcinoma 
has been established [27-29]. On the other hand, a 
study by Delehedde et al. [30] in 1999 showed 
evidence of a markedly increased expression of 
the Bax and Bak protein in tissue sections of 
squamous cell carcinomas of the skin, which was 
later corroborated by other tissue section studies 
where it was shown that Bax expression was 
maintained in oral and skin epithelial dysplasias 
[31,32].
 
 
Surprisingly, only a few studies have focused 
especially on the expression of Bax and Bak in 
carcinomas of the uterine cervix and their 
precancerous lesions rather than squamous cell 
carcinomas in general. As early as 1998, a study 
by Kokawa et al.
 
[33] showed that Bax expression, 
while strong in cervical adenocarcinomas, was 
rather weak in squamous carcinomas. However, a 
large study of primary cervical carcinomas 
demonstrated diffuse cytoplasmic Bax staining in 
83% of the examined cases, although no 
correlation with other prognostic factors was 
proved [34]. In another study by Cheah and Looi 
[35] there was upregulation of Bax in cervical 
carcinoma as opposed to normal cervical tissue but 
not in high-grade squamous intraepithelial 
dysplasia. Other studies compared Bax and Bak 
expressions amongst tissue samples with 
precancerous lesions and cervical carcinomas. In a 
study by Cheung et al. in 2001 [36], there was a 
statistically significant reduction in Bak 
expression in carcinoma as opposed to high-grade 
intraepithelial dysplasia, but no corresponding 
reduction in Bax expression. It should be noted 
that in all the aforementioned studies Bax and Bak 
expression was measured by 
immunohistochemistry on tissue sections, whereas 
in our study we utilized immunocytochemistry 
staining of cytocentrifuged ThinPrep samples of 
cervical smears.  
Another issue of interest is the impact of HPV 
oncoproteins on Bax and Bak expression in 
squamous cells following irradiation or 
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chemotherapy. In most studies investigating this 
topic impaired apoptosis following irradiation or 
chemotherapy treatment was observed in 
HPV-positive cells, which coincided with reduced 
steady-state levels of both Bak and Bax [37-41]. 
More particularly a study by Struijk et al. in 2007 
demonstrated that Bak expression was lower only 
in HPV 5 and HPV 38-containing squamous cells, 
whereas the expression of Bax was lower in HPV 
5 and HPV 8-containing cells but not in HPV 16 
and HPV 38-containing ones [40]. In other studies, 
however, although resistance to 
chemotherapy-induced apoptosis is indeed 
observed in HPV 16 positive cell lines, Bax 
expression is unaffected, suggesting that there are 
other mechanisms by which high-risk HPV types 
interfere with apoptosis mechanisms [42]. Clearly 
the oncoproteins of the various HPV types have 
varying effects on the apoptosis functionality of 
the squamous cells, but nevertheless it is 
undeniable that they play a critical role in 
apoptosis regulation and cell immortalization. It 
seems, however, that although impaired, apoptosis 
is not completely suppressed by HPV oncoproteins. 
A study by Sultana et al. showed that after 
chemotherapy Bax expression was observed more 
frequently in the subgroup of patients who 
responded to the treatment [43], whereas Struijk et 
al. demonstrated evidence that after exposure  to 
UVB irradiation the expressions of both Bax and 
Bak increased to levels comparable to those of 
control cells [40].
 
While molecular studies have revealed that 
HPV E6 is directly involved in the degradation of 
several apoptotic proteins, including Bax and Bak 
[21,44],
 
that fact alone does not suffice to explain 
the mechanism by which HPV infection causes 
carcinogenesis in squamous cells or the evident 
discrepancies between HPV-infected women’s 
potential for developing cervical cancer. This 
variation is probably due to a number of factors, 
both viral and host ones, such as variations in the 
HPV genome, E6 and E7 expression, p53 
pleomorphism and others. Even within HPV 16 
alone five phylogenetic variants were identified 
which seem to demonstrate varying levels of viral 
activities such as p53 degradation and Bax 
down-regulation [45] so it is more than probable 
that such variations also exist among the different 
HPV types and their respective variants, making it 
all the more difficult to predict the biological 
behavior of HPV-infected squamous cells. It is 
therefore of importance to identify possible 
prognostic factors in HPV-infected women, and 
since there is substantial evidence that HPV 
oncoproteins directly influence the expression of 
Bax and Bak proteins it is only logical that these 
proteins be tested as potential prognostic markers. 
Although it has been already established by 
molecular and immunohistochemical studies that 
Bax and Bak expression is affected in 
HPV-infected women, it has not yet been 
investigated whether this altered expression would 
be evident in immunocytochemical staining of 
cells of a routine Pap smear, which is currently the 
easiest and most frequently performed cervical 
cancer screening test. The aim of our study was to 
investigate that particular possibility, in the hope 
of identifying a marker of potential prognostic 
significance that could be easily detected with a 
relatively simple examination. In each patient the 
same ThinPrep sample was utilized both for HPV 
subtyping and Bax and Bak immunocytochemical 
staining for the purpose of consistency, while a 
conventional Pap smear taken concurrently served 
for cytological evaluation of the patients. 
According to our results, there seemed to be  no 
statistically significant difference in the 
expression of Bax or Bak in women positive for 
HPV compared with the control group. However,  
according to the post hoc power calculation the 
power of this study was low, which means there is 
a high probability of a Type II error, namely a 
false assumption that there is no 
statistically significant difference in the Bax and 
Bak scores between HPV infected women and the 
control group. According to Onwuegbuzie and 
Leech, t-test studies with nonsignificant statistical 
differences found and low post hoc power need to 
be replicated independently, and preferably on 
larger sample sizes in order to determine the 
reliability of the nonsignificant statistical 
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difference [46].  Moreover, further studies will 
also be required to determine whether a 
statistically significant difference might become 
apparent with other more complex methods such 
as immunoblotting analysis and mRNA 
expression. 
Furthermore, the oncoproteins of HPV 16 and 
HPV 18 in particular have been known by 
previous studies to target various apoptotic 
molecules, including Bax and Bak [13], a fact 
which has not been established for other HPV 
types, even high-risk ones. Therefore, despite the 
relatively small number of women infected by 
HPV 16 and HPV 18 in our study we performed an 
additional statistical analysis to detect possible 
statistical differences in the expression of Bax and 
Bak in squamous cervical cells of women infected 
by those two types compared to other HPV types. 
In our results there were no 
statistically significant differences, however due 
to the small number of cases and low statistical 
power of the study it is the authors’ opinion that 
larger studies will be required in order to confirm 
this result.  
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